New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

about

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q47279052

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@en

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@nl

type

Item

label

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@en

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@nl

prefLabel

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@en

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.

@nl

P1476

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes

@en

P2093

Agata Maria Rabuazzo

http://www.w3.org/2001/XMLSchema#string

Antonino Di Pino

http://www.w3.org/2001/XMLSchema#string

Francesco Purrello

http://www.w3.org/2001/XMLSchema#string

Salvatore Piro

http://www.w3.org/2001/XMLSchema#string

Viviana Ferrara

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Mechanism of action of fibrates on lipid and lipoprotein metabolism

A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia

Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

P2888

s00592-017-1089-4

P304

209-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00592-017-1089-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Urbano

Roberto Scicali

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29260404

http://www.w3.org/2001/XMLSchema#string